Clinical Research

Expert panelists from Advarra’s gene therapy virtual symposium address some of the most popular questions submitted by the audience. Read part 2:

With increased efforts to engage and include patient and participant communities more closely in research, when does an IRB review become required?

The pandemic has brought biosafety to the spotlight. This blog discusses guidelines and safety precautions for handling COVID-19 specimens.

Complex trial designs can eliminate less-promising investigational treatments quickly to speed development, but they remain under-utilized. Read more:

On Clinical Trials Day, now more than ever, it’s important to recognize and thank those unsung heroes at the focal point of research: research sites and institutions. Read more:

The coronavirus pandemic has brought genetic research to the forefront. To address emerging issues, Advarra presents its first virtual symposium. Read more:

Recent regulations and policies have many institutions establishing policies and processes for working with an external sIRB. Read more:

We have addressed the most popular Q&A topics from our recent webinar on the research impact of COVID-19 in this blog post. Read more:

The difference between “public” and “private” internet spaces has gained importance with the growing research use of internet and social media platforms as data sources. Read more:

Many studies do not accrue subjects at the site level, which contributes to a significant amount of waste of staff time and monetary resources. Read more:

If the clinical development time of a new treatment is to ever decrease, reducing the time in study activation is necessary so actual research can be done.

Research doesn’t just inform medical treatment; it informs public health and public policy, and it helps explain human behaviors. Read more: